NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
The completion of the oral gummy formulation marks a significant milestone for NanoViricides, as it provides a patient-friendly dosage form that could enhance compliance and ease of administration in clinical settings. NV-387 is a unique broad-spectrum antiviral drug designed to treat a range of viral infections, including RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections. According to the company, NV-387 has also demonstrated effectiveness in animal models for monkeypox, smallpox, and measles, positioning it as a potential therapeutic option for emerging viral threats.
The upcoming presentation at the NIBA conference is expected to provide investors and analysts with an update on the company’s development pipeline, including timelines for the Phase II monkeypox trial. The conference, which brings together investment professionals and emerging growth companies, offers NanoViricides a platform to showcase its nanotechnology-based antiviral approach. Anil R. Diwan, who holds a PhD in organic chemistry and has led the company since its inception, will discuss the broader implications of the company’s platform and the progress of its lead drug candidate.
NanoViricides is a clinical-stage company that creates special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is now focused on advancing NV-387 into Phase II human clinical trials, with the monkeypox indication being the first to move forward. The choice of the Democratic Republic of Congo for the trial is strategic, as the country has experienced recurrent monkeypox outbreaks and represents a region with high unmet medical need.
In addition to NV-387, the company is developing NV-HHV-1 for the treatment of all herpesvirus infections, including HSV-1 “cold sores,” HSV-2 “genital ulcers,” VZV shingles, and chickenpox. However, the company has noted that it cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.
Investors can find the latest news and updates relating to NNVC in the company’s newsroom at https://ibn.fm/NNVC. For more information about NanoViricides, visit its website at https://www.nanoviricides.com.
